Combination benefit of amlodipine plus atorvastatin treatment on carotid atherosclerosis in Zucker metabolic rats

Hiromi Kawai, Tomoko Kurata, Kentaro Deguchi, Shoko Deguchi, Toru Yamashita, Yasuyuki Ohta, Yoshio Omote, Syoichiro Kono, Koji Abe

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: Obesity is the major risk factor for metabolic syndrome and atherosclerotic cardiocerebrovascular diseases. Methods: We studied effects of amlodipine, atorvastatin, and their combination on carotid arteriosclerotic processes in a metabolic syndrome model of Zucker fatty rats. Zucker fatty rats were treated with vehicle, amlodipine, atorvastatin, or combination amlodipine plus atorvastatin for 28 days. Results: Compared with the single treatment with amlodipine or atorvastatin, the combination of amlodipine plus atorvastatin treatment prevented arteriosclerotic processes, and induced a strong recovery of Sirtuin1 (Sirt1) expression and a marked reduction in p53, p21, and monocyte chemoattractant protein-1 (MCP-1). Discussion: As Sirt1 is a longevity gene that prevents endothelial atherosclerotic processes, and p53, p21, and MCP-1 play pivotal roles in the initiation and development of atherosclerosis, these data suggest a strong synergistic benefit of combination therapy with amlodipine and atorvastatin for preventing atherosclerotic processes, and potentially reducing the clinical risk of cerebrovascular events in metabolic obesity patients.

Original languageEnglish
Pages (from-to)181-186
Number of pages6
JournalNeurological Research
Volume35
Issue number2
DOIs
Publication statusPublished - 2013

Fingerprint

Zucker Rats
Carotid Artery Diseases
Chemokine CCL2
Therapeutics
Obesity
atorvastatin drug combination amlodipine
Atherosclerosis
Genes

Keywords

  • Amlodipine
  • Atorvastatin
  • Common carotid artery
  • Zucker fatty rat

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Combination benefit of amlodipine plus atorvastatin treatment on carotid atherosclerosis in Zucker metabolic rats. / Kawai, Hiromi; Kurata, Tomoko; Deguchi, Kentaro; Deguchi, Shoko; Yamashita, Toru; Ohta, Yasuyuki; Omote, Yoshio; Kono, Syoichiro; Abe, Koji.

In: Neurological Research, Vol. 35, No. 2, 2013, p. 181-186.

Research output: Contribution to journalArticle

@article{e8c4348cba254615a4742ebb8829e0c6,
title = "Combination benefit of amlodipine plus atorvastatin treatment on carotid atherosclerosis in Zucker metabolic rats",
abstract = "Objectives: Obesity is the major risk factor for metabolic syndrome and atherosclerotic cardiocerebrovascular diseases. Methods: We studied effects of amlodipine, atorvastatin, and their combination on carotid arteriosclerotic processes in a metabolic syndrome model of Zucker fatty rats. Zucker fatty rats were treated with vehicle, amlodipine, atorvastatin, or combination amlodipine plus atorvastatin for 28 days. Results: Compared with the single treatment with amlodipine or atorvastatin, the combination of amlodipine plus atorvastatin treatment prevented arteriosclerotic processes, and induced a strong recovery of Sirtuin1 (Sirt1) expression and a marked reduction in p53, p21, and monocyte chemoattractant protein-1 (MCP-1). Discussion: As Sirt1 is a longevity gene that prevents endothelial atherosclerotic processes, and p53, p21, and MCP-1 play pivotal roles in the initiation and development of atherosclerosis, these data suggest a strong synergistic benefit of combination therapy with amlodipine and atorvastatin for preventing atherosclerotic processes, and potentially reducing the clinical risk of cerebrovascular events in metabolic obesity patients.",
keywords = "Amlodipine, Atorvastatin, Common carotid artery, Zucker fatty rat",
author = "Hiromi Kawai and Tomoko Kurata and Kentaro Deguchi and Shoko Deguchi and Toru Yamashita and Yasuyuki Ohta and Yoshio Omote and Syoichiro Kono and Koji Abe",
year = "2013",
doi = "10.1179/1743132812Y.0000000131",
language = "English",
volume = "35",
pages = "181--186",
journal = "Neurological Research",
issn = "0161-6412",
publisher = "Maney Publishing",
number = "2",

}

TY - JOUR

T1 - Combination benefit of amlodipine plus atorvastatin treatment on carotid atherosclerosis in Zucker metabolic rats

AU - Kawai, Hiromi

AU - Kurata, Tomoko

AU - Deguchi, Kentaro

AU - Deguchi, Shoko

AU - Yamashita, Toru

AU - Ohta, Yasuyuki

AU - Omote, Yoshio

AU - Kono, Syoichiro

AU - Abe, Koji

PY - 2013

Y1 - 2013

N2 - Objectives: Obesity is the major risk factor for metabolic syndrome and atherosclerotic cardiocerebrovascular diseases. Methods: We studied effects of amlodipine, atorvastatin, and their combination on carotid arteriosclerotic processes in a metabolic syndrome model of Zucker fatty rats. Zucker fatty rats were treated with vehicle, amlodipine, atorvastatin, or combination amlodipine plus atorvastatin for 28 days. Results: Compared with the single treatment with amlodipine or atorvastatin, the combination of amlodipine plus atorvastatin treatment prevented arteriosclerotic processes, and induced a strong recovery of Sirtuin1 (Sirt1) expression and a marked reduction in p53, p21, and monocyte chemoattractant protein-1 (MCP-1). Discussion: As Sirt1 is a longevity gene that prevents endothelial atherosclerotic processes, and p53, p21, and MCP-1 play pivotal roles in the initiation and development of atherosclerosis, these data suggest a strong synergistic benefit of combination therapy with amlodipine and atorvastatin for preventing atherosclerotic processes, and potentially reducing the clinical risk of cerebrovascular events in metabolic obesity patients.

AB - Objectives: Obesity is the major risk factor for metabolic syndrome and atherosclerotic cardiocerebrovascular diseases. Methods: We studied effects of amlodipine, atorvastatin, and their combination on carotid arteriosclerotic processes in a metabolic syndrome model of Zucker fatty rats. Zucker fatty rats were treated with vehicle, amlodipine, atorvastatin, or combination amlodipine plus atorvastatin for 28 days. Results: Compared with the single treatment with amlodipine or atorvastatin, the combination of amlodipine plus atorvastatin treatment prevented arteriosclerotic processes, and induced a strong recovery of Sirtuin1 (Sirt1) expression and a marked reduction in p53, p21, and monocyte chemoattractant protein-1 (MCP-1). Discussion: As Sirt1 is a longevity gene that prevents endothelial atherosclerotic processes, and p53, p21, and MCP-1 play pivotal roles in the initiation and development of atherosclerosis, these data suggest a strong synergistic benefit of combination therapy with amlodipine and atorvastatin for preventing atherosclerotic processes, and potentially reducing the clinical risk of cerebrovascular events in metabolic obesity patients.

KW - Amlodipine

KW - Atorvastatin

KW - Common carotid artery

KW - Zucker fatty rat

UR - http://www.scopus.com/inward/record.url?scp=84874629244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874629244&partnerID=8YFLogxK

U2 - 10.1179/1743132812Y.0000000131

DO - 10.1179/1743132812Y.0000000131

M3 - Article

C2 - 23336931

AN - SCOPUS:84874629244

VL - 35

SP - 181

EP - 186

JO - Neurological Research

JF - Neurological Research

SN - 0161-6412

IS - 2

ER -